Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone. Enovis also provides orthobiologic solutions and surgical accessories via EBI, as well as custom and off-the-shelf orthotic braces and supports through its SmartStep and LITOS product lines.

Enovis serves surgeons, hospitals and rehabilitation specialists across North America, Europe and select Asia-Pacific regions, leveraging an integrated commercial network of direct sales teams and distribution partners. The company invests in clinical research and training programs to support product adoption, surgical education and patient outcomes.

Headquartered in Pittsburgh, Pennsylvania, Enovis is led by an executive team with extensive experience in medical device innovation and global market development. The company remains committed to expanding its portfolio through targeted acquisitions and continued R&D aimed at improving functional recovery and quality of life for patients worldwide.

Key Stats

• Today's Range: $20.65 to $21.88
• 50-Day Range: $21.21 to $27.27
• 52-Week Range: $20.55 to $36.82
• Volume: 563,708 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.50
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 84% of companies evaluated by MarketBeat, and ranked 107th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Enovis has a consensus price target of $44.50, representing about 107.8% upside from its current price of $21.42.

Amount of Analyst Coverage

Enovis has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 9.04%

Earnings Growth

Earnings for Enovis are expected to grow by 9.04% in the coming year, from $3.65 to $3.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.48% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 8.01.

Change versus previous month

Short interest in Enovis has recently increased by 2.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

Enovis has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Enovis this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ENOV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Enovis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $68,960.00 in company stock, which represents 0.0056% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $68,960.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/12/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 7,802
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Enovis: $44.50
• High Price Target: $52.00
• Low Price Target: $36.00
• Potential Upside/Downside: +105.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.94
• P/E Growth: N/A
• Net Income: -$1.18 billion
• Net Margins: -49.92%
• Pretax Margin: -48.34%
• Return on Equity: 10.32%
• Return on Assets: 4.57%

Debt

• Debt-to-Equity Ratio: 0.87
• Current Ratio: 2.04
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $2.25 billion
• Price / Sales: 0.56
• Cash Flow: $26.45 per share
• Price / Cash Flow: 0.82
• Book Value: $26.09 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 57,560,000
• Free Float: 55,894,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: 1.38